| Not Yet Recruiting | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma NCT07029776 | University of Arkansas | Phase 2 |
| Not Yet Recruiting | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (N NCT07428369 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Not Yet Recruiting | A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX NCT07477587 | Shanghai Henlius Biotech | Phase 1 |
| Not Yet Recruiting | BR101 in Patients With Relapsed/Refractory Multiple Myeloma NCT07537049 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refracto NCT07429721 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Recruiting | CAR-T Immunomonitoring in Multiple Myeloma (CART I5M) NCT07342179 | Poitiers University Hospital | N/A |
| Recruiting | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multi NCT07280013 | C4 Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients NCT07253103 | University of Salamanca | N/A |
| Not Yet Recruiting | Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma NCT07353554 | Peking Union Medical College Hospital | N/A |
| Not Yet Recruiting | Moving Foward With Myeloma (MFM) NCT07236502 | Medical College of Wisconsin | N/A |
| Not Yet Recruiting | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0 NCT07399444 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Not Yet Recruiting | Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma NCT07376733 | Universidad Complutense de Madrid | N/A |
| Recruiting | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexame NCT07297329 | Sinocelltech Ltd. | Phase 3 |
| Recruiting | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Ta NCT07107529 | European Myeloma Network B.V. | Phase 2 |
| Not Yet Recruiting | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies NCT07107204 | Biotroy Therapeutics | Phase 1 / Phase 2 |
| Recruiting | An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection NCT07101705 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Not Yet Recruiting | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients NCT07181239 | Keymed Biosciences Co.Ltd | Phase 3 |
| Recruiting | Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guide NCT06974786 | SCRI Development Innovations, LLC | Phase 2 |
| Not Yet Recruiting | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies NCT07113496 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Recruiting | Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies NCT07051850 | Sung-Soo Park | — |
| Not Yet Recruiting | Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions NCT06720207 | Shanghai East Hospital | — |
| Not Yet Recruiting | Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Tr NCT07034755 | The Affiliated Hospital of Xuzhou Medical University | N/A |
| Recruiting | Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell NCT07085559 | Anhui Provincial Hospital | EARLY_Phase 1 |
| Recruiting | Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myel NCT07014865 | Azienda USL Reggio Emilia - IRCCS | — |
| Not Yet Recruiting | A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and NCT06925958 | The First Affiliated Hospital of Soochow University | N/A |
| Not Yet Recruiting | Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in th NCT06888856 | Tel-Aviv Sourasky Medical Center | — |
| Recruiting | Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in NCT06821880 | Medical University Innsbruck | — |
| Not Yet Recruiting | Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of NCT06817759 | Ciusss de L'Est de l'Île de Montréal | N/A |
| Recruiting | A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence NCT06767254 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Active Not Recruiting | Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma Patients NCT07088783 | Ozlem | N/A |
| Recruiting | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409 | IDP Discovery Pharma S.L. | Phase 1 / Phase 2 |
| Terminated | CART-38 in Adult AML and MM Patients NCT05442580 | University of Pennsylvania | Phase 1 |
| Active Not Recruiting | Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution NCT07214324 | Azienda USL Reggio Emilia - IRCCS | — |
| Unknown | Serum NGAL IN Patients With Multiple Myeloma NCT05439538 | Assiut University | — |
| Completed | Rehabilitation Management for Patients with Multiple Myeloma NCT06838065 | Azienda USL Reggio Emilia - IRCCS | — |
| Completed | Phase I Trial of GR1803 Injection in Patients With RRMM NCT07102706 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) NCT04721002 | AbbVie | — |
| Terminated | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractor NCT04702425 | Novartis Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma NCT04649073 | Otsuka Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies NCT05513612 | Shanghai Pudong Hospital | Phase 1 |
| Terminated | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multip NCT04178902 | AbbVie | Phase 1 |
| Terminated | A Study of WVT078 in Patients With Multiple Myeloma (MM) NCT04123418 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications NCT03018405 | Celyad Oncology SA | Phase 1 / Phase 2 |
| Completed | An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myelom NCT02211014 | Acerta Pharma BV | Phase 1 |
| Completed | Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCy NCT02203643 | Mario Boccadoro | Phase 2 |
| Unknown | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer NCT02240537 | Benovus Bio, Inc. | Phase 1 |
| Completed | Study Evaluating Venetoclax in Subjects With Hematological Malignancies NCT02265731 | AbbVie | Phase 1 / Phase 2 |
| Completed | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-C NCT02920697 | Institut de Recherches Internationales Servier | Phase 1 |
| Terminated | Phase I Study of Milatuzumab for Graft Versus Host Disease NCT01663766 | Gilead Sciences | Phase 1 |
| Completed | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders NCT01919086 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malig NCT01413568 | Polyphor Ltd. | Phase 1 / Phase 2 |
| Completed | Tumor Registry of Lymphatic Neoplasia NCT00889798 | iOMEDICO AG | — |
| Completed | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies NCT00710528 | Gilead Sciences | Phase 1 |